Eric A. Murphy
Impact in
- Cancer Research top 5%
- MicroRNA in disease regulation
- Cancer, Hypoxia, and Metabolism
- Biomaterials top 5%
- Nanoparticle-Based Drug Delivery
Papers in
-
- Angiogenesis and VEGF in Cancer 4
- Melanoma and MAPK Pathways 3
-
- Hippo pathway signaling and YAP/TAZ 3
- Cellular Mechanics and Interactions 2
- Co-authors
- David A. Cheresh (10 shared papers)Sara M. Weis (5 shared papers)David J. Shields (6 shared papers)Bharat K. Majeti (4 shared papers)Lisette M. Acevedo (4 shared papers)Lea Scheppke (3 shared papers)Leo A. Barnes (3 shared papers)Wolfgang Wrasidlo (2 shared papers)
- Journals
- Proceedings of the National Academy of Sciences (3 papers)Cancer Research (3 papers)Nature Medicine (2 papers)Journal of Clinical Oncology (2 papers)Journal of Medicinal Chemistry (2 papers)
- Partner nations
- United States
In The Last Decade
Eric A. Murphy
22 papers receiving 2.0k citations
Eric A. Murphy's Hit Papers
Peers
Comparison fields: 5 of 107
- Cancer Research 487
- Biomaterials 346
- Immunology and Allergy 129
- Molecular Biology 1.2k
- Oncology 323
Countries citing papers authored by Eric A. Murphy
This map shows the geographic impact of Eric A. Murphy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric A. Murphy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric A. Murphy more than expected).
Fields of papers citing papers by Eric A. Murphy
This network shows the impact of papers produced by Eric A. Murphy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric A. Murphy. The network helps show where Eric A. Murphy may publish in the future.
Co-authors
The 25 scholars most cited alongside Eric A. Murphy, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | A role for VEGF as a negative regulator of pericyte function and vessel maturation Hit paper breakdown → | 2008 | 532 |
| 2 | 2010 | 436 | |
| 3 | 2008 | 414 | |
| 4 | 1996 | 131 | |
| 5 | 2011 | 120 | |
| 6 | 2009 | 80 | |
| 7 | 2011 | 74 | |
| 8 | 2009 | 56 | |
| 9 | 2011 | 55 | |
| 10 | 2010 | 52 | |
| 11 | 2012 | 33 | |
| 12 | 2024 | 12 | |
| 13 | 2021 | 9 | |
| 14 | 2001 | 8 | |
| 15 | 2014 | 8 | |
| 16 | 2022 | 7 | |
| 17 | 2024 | 6 | |
| 18 | 2010 | 5 | |
| 19 | 2014 | 4 | |
| 20 | 2009 | 3 |
About Eric A. Murphy
Eric A. Murphy is a scholar working on Molecular Biology, Cell Biology, Oncology, Immunology and Allergy and Pulmonary and Respiratory Medicine, having authored 22 papers that have together received 2.0k indexed citations. Recurring topics across this work include Cell Adhesion Molecules Research (5 papers), Angiogenesis and VEGF in Cancer (4 papers), Hippo pathway signaling and YAP/TAZ (3 papers), Melanoma and MAPK Pathways (3 papers), Lung Cancer Treatments and Mutations (3 papers), Monoclonal and Polyclonal Antibodies Research (2 papers), Cellular Mechanics and Interactions (2 papers) and HER2/EGFR in Cancer Research (2 papers). The work is most often cited by research in Cancer Research (487 citations), Biomaterials (346 citations), Immunology and Allergy (129 citations), Molecular Biology (1.2k citations) and Oncology (323 citations). Eric A. Murphy has collaborated with scholars based in United States. Frequent co-authors include David A. Cheresh, Sara M. Weis, David J. Shields, Bharat K. Majeti, Lisette M. Acevedo, Lea Scheppke, Leo A. Barnes, Wolfgang Wrasidlo, Milan Makale and Joshua I. Greenberg. Their work appears in journals such as Proceedings of the National Academy of Sciences, Cancer Research, Nature Medicine, Journal of Clinical Oncology and Journal of Medicinal Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.